Bio-Path Holdings Inc. (NASDAQ: BPTH) Stock Information | RedChip

Bio-Path Holdings Inc. (NASDAQ: BPTH) Listen to this Section


$1.48
-0.0350 ( -2.32% ) 56.3K

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Market Data


Open


$1.48

Previous close


$1.51

Volume


56.3K

Market cap


$3.10M

Day range


$1.47 - $1.61

52 week range


$1.31 - $21.60

Insider Ownership Transactions

Total Amount Purchased: -34,537.00 | $ -50,942.08

Date Type Amount Purchased Purchaser
2024-08-01 Sale -25000.00 Nielsen Peter Henry
2024-08-01 Sale -3537.00 MORRIS DOUGLAS P
2024-08-01 Sale -2000.00 Cleaver Heath
2024-08-01 Sale -2000.00 Aubert Paul
2024-08-01 Sale -2000.00 Sherwood Aline

SEC Fillings


Form Type Description Pages Date
8-k 8K-related 15 Aug 15, 2024
10-q Quarterly Reports 51 Aug 14, 2024
4 Insider transactions 1 Aug 01, 2024
4 Insider transactions 1 Aug 01, 2024
4 Insider transactions 1 Aug 01, 2024
4 Insider transactions 1 Aug 01, 2024
4 Insider transactions 1 Aug 01, 2024
8-k 8K-related 15 Jul 11, 2024
8-k 8K-related 13 Jun 14, 2024
8-k 8K-related 15 Jun 14, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.